TY - JOUR
T1 - Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice
T2 - A Modified Delphi Study
AU - Ramasamy, Karthik
AU - Avet-Loiseau, Hervé
AU - Hveding Blimark, Cecilie
AU - Delforge, Michel
AU - Gay, Francesca
AU - Manier, Salomon
AU - Martinez-Lopez, Joaquín
AU - Mateos, Maria Victoria
AU - Mohty, Mohamad
AU - van de Donk, Niels W. C. J.
AU - Weisel, Katja
N1 - Funding Information: Writing and editorial support for the development of this publication was provided by Ying Jean, PhD and Delisa O’Brien of Ashfield MedComms (New York, NY), an Inizio Company; funding was provided by the study sponsor. The authors had full control of the publication and provided their final approval of all content. The Delphi meetings were facilitated by Leon Newman, PhD, and Kindiya Geghman, PhD, of Ashfield MedComms, and funded by the study sponsor. The authors would like to thank the following experts who participated as members of the expert panel in this modified Delphi study: Heinz Ludwig from Austria; Chantal Doyen, Isabelle Vandebroek, Marie-Christiane Vekemans, and Nathalie Mueleman from Belgium; Raija Silvennoinen from Finland; Aurore Perrot, Florent Malard, and Alexis Talbot from France; Hartmut Goldschmidt, Cyrus Khandanpour, Christoph Scheid, Annamaria Brioli, Markus Munder, Hermann Einsele, Raphael Teipel from Germany; Meletios A. (Thanos) Dimopoulos from Greece; Vitaliy Mykytiv from Ireland; Niccolò Bolli, Stefania Olivamolinet, Pellegrino Musto, Massimo Offidani, Elena Zamagni, Daniele Derudas from Italy; Mark David Levin, Wilfried Roeloffzen, Annemeik Broijl, Inger Nijhof from the Netherlands; Tobias Slördahl from Norway; Catarina Geraldes, Paulo Lucio, Rui Bergantim, Graça Vasconcelos Esteves, and Ana Maria Lopez de Macedo from Portugal; Enrique Colado, Marta Sonia Gonzalez Perez, Javier De la Rubia, Rafael Ríos Tamayo, and Maria Jesus Blanchard from Spain; Markus Hansson from Sweden; Christoph Driessen and Christoph Renner from Switzerland; Sally Moore, Kwee Yong, Matthew Jenner, Guy Pratt, Reuben Benjamin, Supratik Basu, and Rachel Hall from the United Kingdom. Publisher Copyright: © 2023 Wolters Kluwer Health. All rights reserved.
PY - 2023/9/30
Y1 - 2023/9/30
N2 - We used a modified Delphi approach to establish areas of consensus and nonconsensus regarding the utility of determining measurable residual disease (MRD) to assess multiple myeloma (MM) treatment response, which may inform disease management and design of future clinical trials. This modified Delphi study incorporated 2 iterative rounds of surveys to evaluate the opinions of an expert panel of 61 practicing hematological oncologists from across 14 countries in Europe concerning the use of MRD testing in MM management. Survey 1 assessed experts' opinions on MRD testing in different clinical situations and associated challenges. Survey 2 focused on the lack of consensus areas identified in survey 1. Consensus to an individual question was defined a priori as 75% agreement or disagreement by the panel. From the 2 rounds of surveys, the experts reached consensus agreement that MRD testing should be performed in newly diagnosed or relapsed patients who achieved complete response (CR) or better after transplantation. In transplant-ineligible patients, experts recommended MRD testing in those who are ≤70 years old and in CR. If a patient was previously positive on positron-emission tomography and computed tomography (PET/CT), both MRD and PET/CT should be assessed at CR. MRD testing should be performed ≤6 months after transplantation and every 6-12 months in continuously treated patients in CR. There was no consensus on making treatment decisions based on MRD status. MRD testing is an important component of clinical management in MM. Additional data will further clarify the role of MRD in guiding treatment decisions.
AB - We used a modified Delphi approach to establish areas of consensus and nonconsensus regarding the utility of determining measurable residual disease (MRD) to assess multiple myeloma (MM) treatment response, which may inform disease management and design of future clinical trials. This modified Delphi study incorporated 2 iterative rounds of surveys to evaluate the opinions of an expert panel of 61 practicing hematological oncologists from across 14 countries in Europe concerning the use of MRD testing in MM management. Survey 1 assessed experts' opinions on MRD testing in different clinical situations and associated challenges. Survey 2 focused on the lack of consensus areas identified in survey 1. Consensus to an individual question was defined a priori as 75% agreement or disagreement by the panel. From the 2 rounds of surveys, the experts reached consensus agreement that MRD testing should be performed in newly diagnosed or relapsed patients who achieved complete response (CR) or better after transplantation. In transplant-ineligible patients, experts recommended MRD testing in those who are ≤70 years old and in CR. If a patient was previously positive on positron-emission tomography and computed tomography (PET/CT), both MRD and PET/CT should be assessed at CR. MRD testing should be performed ≤6 months after transplantation and every 6-12 months in continuously treated patients in CR. There was no consensus on making treatment decisions based on MRD status. MRD testing is an important component of clinical management in MM. Additional data will further clarify the role of MRD in guiding treatment decisions.
UR - http://www.scopus.com/inward/record.url?scp=85171169287&partnerID=8YFLogxK
U2 - https://doi.org/10.1097/HS9.0000000000000942
DO - https://doi.org/10.1097/HS9.0000000000000942
M3 - Article
C2 - 37663672
SN - 2572-9241
VL - 7
SP - E942
JO - HemaSphere
JF - HemaSphere
IS - 9
ER -